The U.S. Food & Drug Administration approved the use of anticoagulant Pradaxa (Dabigatran) in October 2010. By 2011, more than 500 patients who were using the drug had died, and thousands more had suffered injuries, according to USA Today. In 2014, Pradaxa manufacturer Boehringer Ingelheim Pharmaceuticals agreed to pay $650 million to settle nearly 4,000 federal and state lawsuits. That particular case may have ended two years ago, but Pradaxa victims can still file lawsuits against Boehringer Ingelheim. In fact, at least four class-action lawsuits have been filed in 2016. If you suffered uncontrolled bleeding in your brain, rectum or intestines while taking Pradaxa, or if your loved one died while using the drug, contact Ed Bernstein & Associates. Our legal team will evaluate your case to determine if you have grounds for a lawsuit. Call 702-240-0000 today to schedule a free consultation with a personal injury lawyer in Las Vegas. Plaintiffs Claim Boehringer Ingelheim Pharmaceuticals Concealed the Dangers of Pradaxa The victims of Pradaxa have made several claims against the drug’s manufacturer. Some have argued that the company concealed the dangers that the drug poses to patients. Other plaintiffs argued that Boehringer Ingelheim marketed the drug as safer than Warafin yet the research indicated that Pradaxa was just as likely – or even more likely – to cause bleeding events. The lawsuits also claim that the original label of the drug was inaccurate and lacked important details. For example, the drug’s label did not:
- Warn patients about the potential for gastrointestinal bleeding;
- Explain the dosage requirements according to the patient’s weight;
- Warn patients about the risk of bleeding in elder patients; or
- Warn patients that if a bleeding event occurs, there was no treatment available.